The Role of the HER2 Receptor in Breast Cancer

A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time.

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

I reflect on how a generic mammogram reminder overlooked my experience as a breast cancer survivor and how thoughtful messaging could make a difference.

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.